IME
Asset Logo

Imexhs Limited

🇦🇺 ASX

🩺 HEALTH CARE

Compare
Add to watchlist
👑 Overview

📈 Performance

💵 Cost

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

+ 198.18%
Annual Growth

5 years average annual growth

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

2
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

ImExHS Ltd. engages in the development and sale of its Hiruko software platform. The company is headquartered in Mascot, New South Wales and currently employs 400 full-time employees. The company went IPO on 2005-12-14. The firm develops software-as-a-service imaging solutions that includes a Picture Archiving and Communications System (PACS), a Radiology Information System (RIS), a Cardiology Information System (CIS) and an Anatomical Pathology Laboratory Information System (APLIS). Its solutions are cloud-based, vendor neutral and zero footprint, with no need for installed software. Its radiology services provide radiological diagnostic services to hospitals and medical facilities in Colombia and Spain using IMEXHS medical imaging software. The firm's services business also provides it with medical images and radiologists interpretation and reports to develop artificial intelligence (AI) tools. Its solutions include AQUILA - Radiology, ALULA - Pathology, ANTEROS - cardiology, artificial intelligence and advanced visualization.

📈 Performance

Price History

+300.00%

1M

1Y

10Y

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

0%
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🤓 Advanced information

Technical Info

💰 Price*

$0.48

*Price may be up to 24 hours old

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in IME

2

📊 Total Capital Earnings

$644.27

🔃 Average investment frequency

13 weeks

💵 Average investment amount

$632

Last time a customer invested in IME

128 days
IME investor breakdown
💵 Income of investors

More than 200k

33%

150k - 200k

100k - 150k

50k - 100k

67%

Less than 50k

👶 Age of investors

18 - 25

26 - 34

35 - 90

100%
🙋 Legal gender of investors

Female

50%

Male

50%

Pearlers who invest in IME also invest in...

iShares S&P 500 ETF

IVV

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

🙌 Performance (5Yr p.a)

17.69%

📊 Share price

$55.95 AUD

📈 HIGH PRICE GROWTH

🇺🇸 UNITED STATES

Find Out More

Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The firm is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. The company has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The firm conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamem’s therapeutic potential.

🙌 Performance (5Yr p.a)

53.98%

📊 Share price

$0.03 AUD

🧬 BIOTECHNOLOGY

Audinate Group Ltd. engages in the development and commercialization of audio visual software and hardware. Its principal activity is the development and sale of digital AV networking solutions. Its products include Dante AVIO adapters, software, Dante-enabled products, solutions for manufacturers and solutions for software developers. Dante is a technology platform that distributes digital audio and video signals over computer networks. Dante comprises software and chips, cards and modules that are sold to and integrated inside the AV products of its original equipment manufacturer (OEM) customers. The company also provides a series of products and services for AV professionals, including AVIO adapters and management and control software. Dante replaces all of those connections with a computer network, sending video or hundreds of channels of audio over slender ethernet cables with digital fidelity. Dante is available in over 3,500 products from more than 500 manufacturers.

🙌 Performance (5Yr p.a)

6.89%

📊 Share price

$9.44 AUD

🔨 COMMERCIAL SERVICES & SUPPLIES

ANZ Group Holdings Ltd. operates as a non-operating holding company. The company operates in six divisions: Australia Retail, Australia Commercial, Institutional, New Zealand, Pacific, and Group Center. The Australia Retail division offers a range of banking services, such as home loans, deposits, credit cards and personal loans. The company also offers digital and Internet banking and phone banking. The Australia Commercial division provides a full range of banking products and financial services, including asset financing, across customer segments: small business owners and medium commercial customers. The Institutional division services government, global institutional and corporate customers across Australia, New Zealand and International. The New Zealand division provides personal banking and wealth management services. The Pacific division provides retail products for traditional relationship banking. The Group center supports the operating divisions, including technology, property, and risk management.

🙌 Performance (5Yr p.a)

3.03%

📊 Share price

$31.89 AUD

🏦 BANKING

⚖️ HIGH GOVERNANCE

💰 HIGH DIVIDEND

ASIA.AX was created on 2018-09-18 by BetaShares. The fund's investment portfolio concentrates primarily on information technology equity. The investment objective of the BetaShares Asia Technology Tigers ETF is to provide an investment return that aims to track the performance of the Solactive Asia ex-Japan Technology & Internet Tigers Index (the Index), before taking into account fees and expenses.

🙌 Performance (5Yr p.a)

7.44%

📊 Share price

$8.74 AUD

🇦🇺 EX AUSTRALIA

Want more shares? Try these...

Infinity Mining Ltd. engages in the exploration and development of gold, copper, base metals and lithium mineral properties. These tenements are located in highly prospective Lithium, Nickel, Copper and Gold terranes. The firm's is focused on substantial East Pilbara lithium assets. The Pilbara project tenements comprise an extensive portfolio of Lithium, Gold, Nickel, Copper and Zinc exploration tenements located in the Pilbara region of northwest Western Australia, including the Tambourah South, Tambourah North, Strelley Gorge, Hillside and Panorama Projects. The Tambourah South Project is located 80 kilometers (km) southwest of Marble Bar and 155 km south of Port Headland. The Panorama Project encompasses three tenements and is prospective for a range of target types. The Central Goldfields region is host to deposits of gold, base metals and nickel hosted within greenstone belts and granite intrusives.

📊 Share price

$0.01 AUD

⛏️ MINING

IMLC.AX was created on 2023-08-01 by IML. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to outperform the S&P/ASX 300 Accumulation Index (after fees and expenses and before taxes) on a rolling four-year basis.

📊 Share price

$4.07 AUD

Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. The company is headquartered in Melbourne, Victoria and currently employs 6 full-time employees. The company operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.

🙌 Performance (5Yr p.a)

-2.55%

📊 Share price

$0.10 AUD

🧬 BIOTECHNOLOGY

Imdex Ltd. engages in the provision of mining equipment, technology, and services. The company is headquartered in Balcatta, Western Australia and currently employs 851 full-time employees. The Company’s product offering includes an integrated range of drilling optimization products, cloud connected rock knowledge sensors and data and analytics. Its geographical segments include Americas, Asia Pacific, and Africa/Europe. The Company’s solutions include software, mining technology, drilling optimization, downhole navigation, structural geology, in-field geo-analysis, and driller operable geophysics. Its brands include AMC and REFLEX technologies. Its products include IMDEXHUB-IQ, IMDEX MOBILE, AMC BORE HOLE STABILISER, IMDEX MUD AID, AMC BOS, and AMC SRU Range. Its drilling fluid range include cement & grouting additives, clay & shale stabilizers, drilling fluids equipment, filtrate control agents, flocculants & dispersants, foaming agents & detergents, lost circulation materials, lubricants & cutting oils, specialty products & chemicals, treating chemicals, viscosifiers, and weighting materials.

🙌 Performance (5Yr p.a)

10.94%

📊 Share price

$2.17 AUD

📈 HIGH PRICE GROWTH

🕊️ SOCIALLY AWARE

⛏️ MINING

Compare
Add to watchlist